Today Morgan Stanley Reconfirms a Overweight Rating on Boston Scientific (NYSE:BSX) and a $48 Target Price

October 2, 2018 - By Peter Kolinski

Boston Scientific Corporation (NYSE:BSX) Logo

Investors sentiment increased to 1.2 in 2018 Q2. Its up 0.24, from 0.96 in 2018Q1. It is positive, as 38 investors sold Boston Scientific Corporation shares while 177 reduced holdings. 92 funds opened positions while 167 raised stakes. 1.21 billion shares or 2.60% more from 1.18 billion shares in 2018Q1 were reported.

19,300 were reported by Old Mutual Global Investors (Uk). Los Angeles Capital Mngmt Equity Research Inc holds 0.36% or 1.98M shares in its portfolio. United Asset Strategies Incorporated holds 93,613 shares. Credit Suisse Ag owns 1.75M shares or 0.06% of their US portfolio. Bessemer Group has invested 0% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Oppenheimer Asset Mgmt reported 38,424 shares. Kentucky Retirement Trust Fund owns 25,986 shares for 0.2% of their portfolio. Da Davidson And stated it has 0.02% in Boston Scientific Corporation (NYSE:BSX). Teacher Retirement Of Texas reported 0.06% of its portfolio in Boston Scientific Corporation (NYSE:BSX). 7.52 million were accumulated by Morgan Stanley. First Quadrant Ltd Partnership Ca holds 1.02M shares. Amer Research & invested in 2,000 shares or 0.02% of the stock. Cap Ww Investors has 107.76M shares for 0.75% of their portfolio. Minnesota-based Sit Inv Assoc has invested 0.12% in Boston Scientific Corporation (NYSE:BSX). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Management Corporation reported 146,500 shares stake.

Since April 2, 2018, it had 0 insider buys, and 16 sales for $11.63 million activity. 10,000 shares were sold by Sorenson John Bradley, worth $358,607. Pierce David A sold $152,914 worth of stock. The insider Butcher Arthur C sold 7,500 shares worth $225,413. Another trade for 10,000 shares valued at $358,595 was sold by Wang Xin Warren. Another trade for 116,666 shares valued at $4.19M was made by Mahoney Michael F on Monday, September 10. On Thursday, May 17 the insider Thepaut Eric Francis Yves sold $603,368.

Boston Scientific (NYSE:BSX) Rating Reaffirmed

Boston Scientific (NYSE:BSX) just had their share rating of a ‘Overweight’ issued by research analysts at Morgan Stanley, who now has a $48 TP on the $53.91 billion market cap company or a 23.14 % upside potential. This key information was revealed in a note on Tuesday, 2 October.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Among 13 analysts covering Boston Scientific (NYSE:BSX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Boston Scientific has $42 highest and $3100 lowest target. $36.38’s average target is -6.67% below currents $38.98 stock price. Boston Scientific had 15 analyst reports since April 5, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Wells Fargo on Monday, September 17. The company was maintained on Wednesday, April 25 by Jefferies. The firm earned “Overweight” rating on Thursday, July 26 by Morgan Stanley. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Strong Buy” rating by Raymond James on Thursday, April 26. Bank of America maintained Boston Scientific Corporation (NYSE:BSX) rating on Thursday, April 5. Bank of America has “Buy” rating and $34 target. The stock has “Buy” rating by Needham on Wednesday, April 25. The rating was upgraded by Jefferies to “Buy” on Tuesday, September 4. Stifel Nicolaus maintained Boston Scientific Corporation (NYSE:BSX) rating on Wednesday, April 25. Stifel Nicolaus has “Buy” rating and $3300 target. As per Thursday, April 26, the company rating was maintained by Leerink Swann. Citigroup maintained the stock with “Buy” rating in Tuesday, May 1 report.

The stock increased 1.25% or $0.48 during the last trading session, reaching $38.98. About 8.29 million shares traded or 29.92% up from the average. Boston Scientific Corporation (NYSE:BSX) has risen 25.61% since October 2, 2017 and is uptrending. It has outperformed by 9.99% the S&P500.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on October, 25. They expect $0.34 earnings per share, up 9.68 % or $0.03 from last year’s $0.31 per share. BSX’s profit will be $470.19 million for 28.66 P/E if the $0.34 EPS becomes a reality. After $0.41 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts -17.07 % negative EPS growth.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide. The company has market cap of $53.91 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 102.85 P/E ratio. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

More important recent Boston Scientific Corporation (NYSE:BSX) news were published by: which released: “Boston Scientific (BSX) PT Raised to $48 at Morgan Stanley Following Healthcare Conference” on October 02, 2018, also published article titled: “JP Morgan likes Boston Scientific’s Augmenix buy”, published: “Premarket analyst action – healthcare” on September 04, 2018. More interesting news about Boston Scientific Corporation (NYSE:BSX) was released by: and their article: “7 Stocks to Buy Thanks to Trump’s New Trade Deal” with publication date: October 01, 2018.

Boston Scientific Corporation (NYSE:BSX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.